Introduction
Lung cancer is the leading cause of cancer-related deaths among both males and females in the United States (Landis et al., 1998) . Each year, approximately 171 000 new cases of lung cancer will be diagnosed, and 160 000 individuals will die from the disease. Despite improvements in the detection and treatment of lung cancer in the past two decades, the overall survival remains less than 15% (Ginsberg et al., 1997) . Signi®cant progress has been made towards understanding the genetic changes associated with lung cancer. It is still important to investigate additional molecular alterations that emphasize our knowledge regarding tumorigenesis in non-small cell lung NSCLC.
Methylation is a main epigenetic modi®cation in humans and changes in methylation patterns play an important role in tumorigenesis (Baylin et al., 1998) . In particular, methylation of normally unmethylated CpG islands has been identi®ed as an alternative mechanism for tumor suppressor gene inactivation in human cancer cells (Baylin et al., 1998; Merlo et al., 1995; Jones and Laird, 1999) . In fact, a recent publication reports an association between adenomatous polyposis coli (APC) gene promoter 1A methylation and silencing of its expression in gastric cancer (Tsuchiya et al., 2000) . Several studies report aberrant promoter methylation in various genes in human NSCLC, for example the putative metastasis suppressor gene deathassociated protein (DAP) kinase (Esteller et al., 1999; Tang et al., 2000) , the detoxi®cation gene glutathione S-transferase P1 (GSTP1) (Esteller et al., 1999) , and the DNA repair gene 06-methylguanine-DNA-methyltransferase (MGMT) (Esteller et al., 1999) . Hypermethylation of the DAP kinase promoter was associated with poor survival in patients with stage I NSCLC (Tang et al., 2000) . In addition, we recently reported an association between hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma , suggesting hypermethylation of these genes as markers for biological aggressiveness in these diseases.
The purpose of this study was to determine whether CpG island hypermethylation of the APC promoter 1A occurs in primary NSCLC, and whether the presence or quantity of hypermethylated APC has any relationship with clinical outcome in patients with primary NSCLC.
Results
APC promoter methylation was detectable in 86 (94.5%) of 91 tumor samples, 80 (87.9%) of 91 normal tissue samples of the NSCLC group, and two (20%) of 10 normal lung specimens of the control group. In 69 (75.8%) of 91 patients the APC promoter methylation level, expressed as the ratio between methylated APC and MYOD1 PCR product, was elevated in tumor compared to matching normal tissue (the T/N ratio was higher than 1.0). The median level of APC/ MYOD1 was 4.75 (range: 0.00 ± 240.73) in tumor compared to 1.57 (range: 0.00 ± 73.90) in matching normal tissue (P50.001; Wilcoxon test). However, as shown in Figure 1 , the extreme value in this range (73.9) was due to only one patient. All the rest of the APC/MYOD1 ratios were within the range of 0 ± 19. The median APC methylation level in normal lung tissue of the control group was 0.00 (range: 0.00 ± 5.09), and signi®cantly lower compared to the APC methylation in normal tissue of the NSCLC group (P=0.003; Mann ± Whitney test). Table 1 shows the clinicopathological data and the median APC promoter methylation in tumor tissues of patients with NSCLC. There were no statistical dierences between APC promoter methylation in tumor tissue and clinicopathological factors, such as age, sex, etc. observable. In addition, there was no signi®cant association between smoking history and APC methylation in normal lung tissues from NSCLC patients. The median APC methylation in normal lung tissue was 0.80 (range: 0.15 ± 8.0) for non-smokers and 2.03 (range: 0.00 ± 73.90) for smokers (P=0.253; Mann ± Whitney test).
To determine whether there was any prognostic signi®cance attached to quantitative dierences in APC methylation levels, we used the maximal chi-square method to determine a cut-o value to segregate patients into groups with low and high APC methylation status (Miller and Siegmund, 1982; Halpern, 1982) . Obtaining a T/N APC methylation ratio of 14 as a cut-o, 68 (75%) of patients had a low APC methylation status and 23 (25%) had a high APC methylation status. The median survival was not reached in the low methylation group at the time we did these studies, whereas it was reached in 24.7 months (95% C.I.:17.86; 31.54) in the high methylation group. The observed Tarone-Ware test statistic was 4.05. To determine a P value, we used bootstraplike simulations to estimate the distribution of a maximal chi-square statistic, since the cut-o point of 14 had been chosen after examining the data. The resulting P value was 0.041. The respective survival curves are shown in Figure 2 and show 5-year survival rates of 50.8+0.06% for low-methylated and 37.7+0.1% for high-methylated NSCLC (P=0.04 Wilcoxon-Gahan). The importance of hypermethylated APC DNA as a prognostic factor was next determined by the Cox's proportional hazards model analysis. The logistic regression model included the parameters gender, age, histopathological type, pT (tumor in®ltration) and pN (lymph node involvement) categories, grade of dierention of the primary tumor, and APC methylation status. Signi®cant independent prognostic factors were shown to be the pT (P=0.050) and the pN categories (P50.001), and APC methylation status (P=0.044). Table 2 shows the statistically signi®cant parameters in the regression model.
Discussion
In this study, we measured methylation within the promoter 1A of the APC gene at nine CpG sites in 182 lung tissues from NSCLC patients, and 10 normal lung tissues from patients without cancer. Methylated APC genes were found in a very high percentage (95%) of NSCLC, suggesting a fundamental role for APC methylation in tumorigenesis. However, the intratumoral content of APC methylation at this site varied among the tumors over a range of 240-fold. This observation of seemingly variable amounts of methylated APC among the tumors may have several possible explanations. One is that the tumor consists of a mixture of cells having either methylated or unmethylated APC. In that case, the monoclonal tumor may be heterogeneous, with dierent degrees of APC inactivation among dierent subclones. Another explanation might be heterogeneity of methylation patterns within individual cells at CpG sites. It is possible that transcription of the APC gene could be suppressed by any number of dierent methylation patterns. In that case, the methylation at any speci®c site within the promoter could be variable and the amount of PCR product from that site will vary accordingly. Finally, specimen heterogeneity in terms of stromal cell contamination may be a contributor to the apparent variation in methylation, although it probably does not account for most of the dierence in methylated APC content among the tumor specimens. As we have reported here, the specimens that we obtained for analysis were speci®cally selected to contain a large percentage of malignant cells.
Unexpectedly, we also observed detectable APC methylation in the majority (88%) of non-cancerous tissue taken from the cancer patients at the time of surgery, although at a signi®cantly lower median level than in the tumor tissue. There are several possible explanations for this observation. The low level methylation may re¯ect the in®ltration of neoplastic cells in histologically`normal' surrounding mucosa. It is also possible that the non-malignant tissue, even though it appeared to be histologically normal, has been damaged by environmental factors such as cigarette smoke. The ®nding that there was no signi®cant association between APC promoter methylation and smoking history in the normal lung tissues of patients with NSCLC suggests, however, that this factor does not account for this epigenetic alteration in these tissues. Alternatively, some of the early molecular events of tumorigenesis may have already occurred and indeed, it may be the presence of these changes that predispose this apparently normal tissue to start to undergo a further chain of events leading ultimately to tumor development. From previous studies with gastrointestinal cancers, it is generally agreed that alterations in the APC gene are early events in tumorigenesis. In fact, we have observed methylated APC in Barrett's esophagus, a precancerous condition arising in tissue exposed to chronic acid re¯ux from the stomach . A recent publication reports aberrant APC methylation in nine of 48 (18%) benign colorectal adenomas, a frequency similar to invasive carcinomas (Esteller et al., 2000) .
It is also possible that methylated APC constitutes an age-related event in normal lung tissue. To test this hypothesis, we analysed histological normal lung tissues from a signi®cantly younger group of patients without cancer, and detected methylated APC in only 20% of these patients. These data suggest that APC promoter 1A methylation may constitute an agerelated event in the normal lung, as it does in noncancerous gastric mucosa (Tsuchiya et al., 2000) , and that this event has already occurred in the two normal tissues of the control group. Methylation of genes is known to occur in other normal tissues, such as APC in normal colon mucosa (Hiltunen et al., 1997) , and in normal gastric mucosa, but not in normal esophageal epithelium , and at the D17S5 locus in non-cancerous lung tissues (Eguichi et al., 1997) . These ®ndings suggest that methylation of certain genes may be a much more common occurrence than previously thought, and while tissue-speci®c, may not always be tumor-speci®c.
A recently published study reported APC promoter methylation in 0 of 17 (0%) lung tumor specimens analysed (Esteller et al., 2000) . There are several possible explanations for these apparently discrepant results. First, primers used in the latter study did not cover the same sites in the APC promoter as did ours, and therefore might have ampli®ed sites undergoing infrequent methylation in NSCLC. Secondly, Esteller et al. (2000) determined APC hypermethylation using methylation-speci®c PCR (MSP), whereas quantitative real-time PCR (Taqman 1 ) was used in our study. The reported 10-fold greater sensitivity of the Taqman 1 method may account for these discrepant results .
The most striking ®nding in the current study was that high levels of methylated APC were signi®cantly associated with worse clinical outcome. The extent of change in methylated APC during the normal to tumor tissue transition could be an indicator of the overall methylation propensity of the tumor. A greater propensity for methylation may result in a more aggressive tumor because of increased capability for inactivation of undesirable tumor suppressor genes. This hypothesis is strengthened by the results of a recently published study reporting a correlation between DAP kinase gene methylation and inferior survival in patients with stage I NSCLC (Tang et al., 2000) . Additional studies need to be conducted that will help in assessing the clinical importance of the present ®ndings and to understand possible underlying mechanisms. In particular, the importance of hypermethylated APC DNA as a prognostic marker in the plasma of NSCLC patients has yet to be determined.
In conclusion, this investigation shows that promoter 1A of APC is methylated in the majority of NSCLCs. High levels of APC promoter methylation are signi®cantly associated with inferior survival, showing potential as a marker of biologically aggressive disease. Quantitation of methylated APC may have value in identifying NSCLC patients at high risk of early disease recurrence after surgery, and in selecting patients who will bene®t from intensive adjuvant therapy.
Materials and methods

Patients
Ninety-one patients were included in this study, consisting of 69 (76%) men and 22 (24%) women, with a median age of 63.3 years (range, 34 ± 82). Forty-three (47%) patients had squamous cell carcinomas, 33 (36%) had adenocarcinomas, and 15 (16%) had large cell carcinomas. The primary tumors were graded histopathologically as well-dierentiated (G1, one patient), moderately-dierentiated (G2, 19 patients), and poorly-dierentiated (G3, 71 patients). Tumor staging was performed according to the International Union Against Cancer (UICC) TNM classi®cation: Forty-®ve (49%) had stage I tumors, 19 (21%) had stage II tumors, and 27 (30%) had stage IIIa tumors. All tumors were completely resected (R0 category). Patients with histopathological stage IIIa tumors received postoperative chemotherapy. The median follow-up was 85.9 months (min. 63.3; max. 105.2 months) and no patient was lost to follow-up. Ten histologically normal lung tissue specimen, obtained at surgery or autopsy, from patients with no evidence of cancer were used as a control group. Nine (90%) men and one (10%) woman, with a median age of 46.0 years (range, 1 ± 64) were included in this group.
Tissue acquisition and nucleid acid isolation
Tissue for DNA analysis was obtained immediately after lung resection before starting mediastinal lymphadenectomy and was frozen in liquid nitrogen. Tissue was analysed from the following two locations: tumor and uninvolved lung tissue taken from the greatest distance to the tumor. Six mm frozen sections were taken from blocks of tumor tissue and starting with the ®rst section every 5th was routinely stained with HE and histopathologically evaluated. Sections were pooled for analysis from areas of estimated 75% malignant cells. Genomic DNA was isolated from frozen tissue by standard methods of proteinase K digestion and phenol-chloroform extraction using the GenomicPrep 1 Cells and Tissue DNA Isolation Kit (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) according to the instructions of the manufacturer.
Bisulfite treatment
Sodium bisul®te conversion of genomic DNA was performed as previously described (Olek et al., 1996; Eads et al., 1999) .
Methylation analysis
Templates were ampli®ed by a¯uorescence based, real-time PCR (Taqman 1 ) as previously described (Heid et al., 1996) . In brief, primers and probes were designed to speci®cally amplify bisul®te-converted promoter 1A APC DNA, as well as the internal reference gene, MYOD1. The ratios between the values of the gene of interest versus the internal reference gene obtained by the Taqman 1 analysis were used as a measure for representing the relative level of methylated APC DNA in the particular sample. The primer and probe sequences are listed below. In all cases, the ®rst primer is the forward PCR primer, the second is the reverse PCR primer, and the third is the Taqman 1 probe. The primer and probe sequences are as follows: (a) APC methylation, TTATATGTCGGTTACGTGCGGTTTATAT, GAACCAAAACGCTCCCCAT; 6FAM5'-CCCGTCGAA-AACCCGCCGATTA-3'TAMRA; (b) MYOD1, CCAACTC-CAAATCCCCTCTCTAT, TGATTAATTTAGATTGGGT-TTAGAGAAGGA; 6FAM5'-TCCCTTCCTATTCCTAAA-TCCAACCTAAATACCTCC-3'TAMRA.
Statistical analysis
Taqman
1 analyses yield values that are expressed as ratios between two absolute measurements ([gene of interest/ internal reference]6100). Medians and ranges were calculated for the methylation values and the T/N ratio (tumor/normal) for each patient. Associations between variables were tested by either using Wilcoxon signed rank test or Mann ± Whitney U-test. The signi®cance of rank ordering between variables was tested by using the Kruskal-Wallis analysis of variance for ordinal data. Hazards ratios were used to calculate the relative risks of death. These calculations were based on the Pike estimate, with the use of the observed and expected number of events as calculated in the Tarone-Ware test statistic (Pike, 1972) . The maximal chi-square method was adapted to determine which methylation value best segregated patients into poor-and good prognosis subgroups (in terms of likelihood of surviving), with the Tarone-Ware test as the statistics used to measure the strength of the grouping (Miller and Siegmund, 1982; Halpern 1982) . Multivariate analysis was performed with the Cox proportional hazards regression model. The level of signi®cance was set to P50.05. Analyses were carried out using the SPSS software package (Chicago, IL, USA).
